These transcription factors are ideal for development of mechanism-based drugs since Sp1 expression decreases with age[39-41], and results of animal studies show that Sp1, Sp3 and Sp4 are highly expressed in tumor but not in non-tumor tissues[21,23]. This evidence concerns the gene SP3 and neoplasm.